Introduction: Virus-like particle (VLP) vaccines face significant challenges in their translation
from laboratory models, to routine clinical administration. While some VLP vaccines thrive …

Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last
three decades. VLPs constitute versatile tools in vaccine development due to their …

Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use
of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human …

Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …

Virus-like particles (VLPs) are multiprotein structures that mimic the organization and
conformation of authentic native viruses but lack the viral genome, potentially yielding safer …

Viral infectious diseases threaten human health and global stability. Several vaccine
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …

Virus-like particles are supra-molecular assemblages, usually icosahedral or rod-like
structures. They incorporate key immunologic features of viruses which include repetitive …

Virus-like particles (VLPs) are nanostructures that possess diverse applications in
therapeutics, immunization, and diagnostics. With the recent advancements in biomedical …

Vaccine formulation development has traditionally focused on improving antigen storage
stability and compatibility with conventional adjuvants. More recently, it has also provided an …

The development of virus-like particle (VLP) technology has had an enormous impact on
modern vaccinology. In order to optimize the efficacy and safety of VLP-based vaccines …